Skip to content

Net debt / EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.7×-0.1×
Eli Lilly logo
Eli LillyLLY
1.1×-1.1×
Amgen logo
AmgenAMGN
3.7×-0.7×
Incyte logo
IncyteINCY
-2×-0.8×
AbbVie logo
AbbVieABBV
2.5×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-0.1×0.0×

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Calculated from Protagonist Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Protagonist Therapeutics’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's net debt / EBITDA?
Protagonist Therapeutics (PTGX) reported net debt / EBITDA of -5.1× in Q3 2025.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.